TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder
Brief Summary: This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]).


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo
C: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo
D: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder
Brief Summary: This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]).


Options:
A: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo
C: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2 Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3 Aripiprazole + D-cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole, Drug: D-cycloserine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 Aripiprazole, 3 Aripiprazole + D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 3 Aripiprazole + D-cycloserine
D: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder
Brief Summary: This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]).


Options:
A: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
D: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism
Brief Summary: To determine whether 3 months' anticoagulation is as good as or better than 6 months' for the treatment of DVT/PE


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sodium warfarin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium warfarin | Intervention Type: DRUG; Name: sodium warfarin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Sodium warfarin; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: Vitamin K antagonist (Coumarin anticoagulants); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Duration of anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin duration; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinician Integration Study
Brief Summary: The purpose of this study is to find out if patients with lung cancer and their main informal caregiver (person providing physical, emotional, or financial support) are helped by getting information, support, and decision making tools through a computer system called CHESS(the Comprehensive Health Enhancement Support System)


Options:
A: Arm Label: Experimental: supportive care; Type: EXPERIMENTAL; Interventions: Other: Supportive care | Arm Label: Control: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Supportive care; Assigned to Arm(s): Experimental: supportive care
B: Arm Label: Psychological Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychological intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychological intervention; Assigned to Arm(s): Psychological Intervention
C: Arm Label: Nueva Vida Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nueva Vida Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nueva Vida Intervention; Assigned to Arm(s): Nueva Vida Intervention
D: Intervention Type: DEVICE; Name: Comprehensive Health Enhancement Support System; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain
Brief Summary: The purpose of this study is to examine whether insomnia due to chronic low back pain can improve with use of eszopiclone.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Low dose eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: High dose eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): Low dose eszopiclone | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): High dose eszopiclone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Eszopiclone 3 mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause
Brief Summary: To demonstrate improved subjective sleep in women with insomnia secondary to perimenopause or menopause following treatment with 3 mg of eszopiclone.


Options:
A: Arm Label: Eszopiclone 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 1 mg | Arm Label: Eszopiclone 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg | Arm Label: Eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 3 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zolpidem Tartrate 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem Tartrate 10 mg | Intervention Type: DRUG; Name: Eszopiclone 1 mg; Assigned to Arm(s): Eszopiclone 1 mg | Intervention Type: DRUG; Name: Eszopiclone 2 mg; Assigned to Arm(s): Eszopiclone 2 mg | Intervention Type: DRUG; Name: Eszopiclone 3 mg; Assigned to Arm(s): Eszopiclone 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Zolpidem Tartrate 10 mg; Assigned to Arm(s): Zolpidem Tartrate 10 mg
B: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo
C: Arm Label: eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): eszopiclone | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy
Brief Summary: There is some evidence that supplemental Vitamin D may contribute to quicker recovery from TB when given in addition to normal TB therapy. This needs to be proven with a controlled clinical trial. People receiving Vitamin D with anti TB therapy will be compared against people receiving anti TB therapy alone to see if vitamin D contributes to a quicker recovery (as shown by a quicker sputum culture conversion).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins; Assigned to Arm(s): Multivitamins | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin supplement containing vitamins B, C, and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement containing vitamins B, C, and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: A. 100,000 IU Cholecalciferol per dose of 3.3ml | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: B. Migliol Oil without Cholecalciferol | Intervention Type: DRUG; Name: A. 100,000 IU Cholecalciferol per dose of 3.3ml; Assigned to Arm(s): A | Intervention Type: OTHER; Name: B. Migliol Oil without Cholecalciferol; Assigned to Arm(s): B
D: Arm Label: Vitamin D pill; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D pill | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D pill; Assigned to Arm(s): Vitamin D pill | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo in the Absence of Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.
Brief Summary: Primary:

To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites.

Secondary:

To evaluate the tolerability and safety of satavaptan in the absence of concomitant diuretic drugs over a 52-week treatment period in patients with cirrhosis of the liver and recurrent ascites.

The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).


Options:
A: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: satavaptan (SR121463B); Assigned to Arm(s): N/A
D: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Deep Brain Stimulation for Treatment Resistant Depression
Brief Summary: The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant treatments. Participation in the study will continue for ten years or until the device receives FDA approval for depression. Forty (40) patients will be enrolled in this study.


Options:
A: Arm Label: Intervention Patients & Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PA | Arm Label: Intervention Patients, Control Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PA | Arm Label: Control Patients, Intervention Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Patients & Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non-Randomized Controlled Trial Patients; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PC | Intervention Type: BEHAVIORAL; Name: DECIDE-PA; Assigned to Arm(s): Intervention Patients & Providers, Intervention Patients, Control Providers | Intervention Type: BEHAVIORAL; Name: DECIDE-PC; Assigned to Arm(s): Intervention Providers
B: Arm Label: Deep Brain Stimulation; Type: EXPERIMENTAL; Interventions: Device: Deep Brain Stimulation | Intervention Type: DEVICE; Name: Deep Brain Stimulation; Assigned to Arm(s): Deep Brain Stimulation
C: Arm Label: Implementation Facilitation; Type: EXPERIMENTAL; Interventions: Other: Replicating Effective Programs plus External Facilitation | Arm Label: Educational Materials; Type: PLACEBO_COMPARATOR; Interventions: Other: Educational Materials | Intervention Type: OTHER; Name: Replicating Effective Programs plus External Facilitation; Assigned to Arm(s): Implementation Facilitation | Intervention Type: OTHER; Name: Educational Materials; Assigned to Arm(s): Educational Materials
D: Arm Label: Patient researcher intervention; Type: EXPERIMENTAL; Interventions: Behavioral: peer-driven intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: peer-driven intervention; Assigned to Arm(s): Patient researcher intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Melphalan-Prednisone(MP),MP-THALIDOMIDE,and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma.
Brief Summary: In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been used since the 1960s and is regarded as the standard of care in elderly patients. We assess whether the addition of thalidomide to this combination or adapted high-dose chemotherapy, using a melphalan 100 mg/m2 -based regimen, would improve survival.


Options:
A: Intervention Type: DRUG; Name: Thalidomide/Dexamethasone vs Melphalan/Prednisone; Assigned to Arm(s): N/A
B: Arm Label: Thalidomide; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide, Drug: Melphalan+Prednisolone | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan+Prednisolone | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide | Intervention Type: DRUG; Name: Melphalan+Prednisolone; Assigned to Arm(s): Control, Thalidomide
C: Arm Label: Part 1: VMP+Siltuximab 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab 8.3 mg/kg or 11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm B: VMP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Intervention Type: DRUG; Name: Siltuximab11 mg/kg; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Siltuximab 8.3 mg/kg or 11 mg/kg; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm B: VMP
D: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A

Answer: D